Thomson Reuters Pharma is apparently the world's leading pharmaceutical intelligence service covering the entire drug discovery and development pipeline. The Group provide a quarterly report called The Ones To Watch - the latest report for June 2010 caught my attention.
http://thomsonreuters.com/content/scientific/pdf/ls/pharma_matters/the_ones_to_watch.pdf
Refer to the section titled - The Five Most Promising Drugs Entering Phase II Trials. Yes indeed, one of the five most promising drugs entering FDA phase II trials is none other than NNZ-2566.
Investors may not appear interested in the progress of NNZ-2566 through clinical trials but its caught the attention of industry experts. The report notes that the drug has Fast Track status from the FDA and according to Neuren management, potential sales of over $2 billion in the US alone in the first 10 years.
one to watch
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.44 |
Change
-1.150(7.38%) |
Mkt cap ! $1.918B | |||
| Open | High | Low | Value | Volume |
| $15.38 | $15.40 | $14.40 | $4.588M | 310.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2 | $14.43 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.44 | 284 | 10 |
View Market Depth
| Last trade - 12.43pm 02/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |